A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials.
A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials.
A CB1 receptor ligand with less potency than R-1 methanandamide inhibits electrically evoked contractions in isolated murine vas deferens (IC<sub>50</sub> = 230 nM) binding affinity for CB1 receptors is less than that of AEA (Ki = 175 nM for the
A CB1 receptor ligand with less potency than R-1 methanandamide inhibits electrically evoked contractions in isolated murine vas deferens (IC<sub>50</sub> = 230 nM) binding affinity for CB1 receptors is less than that of AEA (Ki = 175 nM for the
A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials.
A succinimide that is converted to N-desmethylmethosuximide, a channel blocker that targets low threshold calcium currents inhibits CYP2C19-mediated metabolism of biguanides has anticonvulsant properties in clinical trials.